Ozi ndị ọzọ ― Igbo

Erythema multiforme (EM) bụ ọnọdụ ebe ntụpọ dị iche iche na-apụta n'akpụkpọ ahụ na akpụkpọ anụ mucous n'ihi mmeghachi omume mgbochi. Ọ bụ ezie na ọrịa nje na-akpatakarị, karịsịa nje virus herpes simplex (HSV), ma ọ bụ ọgwụ ụfọdụ, a ka amabeghị ihe kpatara ya n'ọtụtụ ọnọdụ. Ịgwọ nnukwu EM na-elekwasị anya n'ibelata mgbaàmà site n'iji ude nwere steroid ma ọ bụ antihistamines. Ijikwa EM ugboro ugboro na-arụ ọrụ kacha mma mgbe e mepụtara atụmatụ ọgwụgwọ onye ọrịa ọ bụla. Ụzọ mbụ gụnyere ọgwụgwọ ọnụ na nke elu. Ndị a gụnyere corticosteroids na ọgwụ mgbochi nje. Ọgwụgwọ ndị dị n'elu gụnyere ude steroid siri ike yana ngwọta maka akpụkpọ anụ mucous emetụtara. Maka ndị ọrịa na-anabataghị ọgwụ nje, nhọrọ nke abụọ gụnyere ọgwụ na-egbochi mgbochi ọrịa, ọgwụ nje, anthelmintics, na ọgwụ ịba.
Erythema multiforme (EM) is an immune-mediated condition that classically presents with discrete targetoid lesions and can involve both mucosal and cutaneous sites. While EM is typically preceded by viral infections, most notably herpes simplex virus (HSV), and certain medications, a large portion of cases are due to an unidentifiable cause. Treatment for acute EM is focused on relieving symptoms with topical steroids or antihistamines. Treatment for recurrent EM is most successful when tailored to individual patients. First line treatment for recurrent EM includes both systemic and topical therapies. Systemic therapies include corticosteroid therapy and antiviral prophylaxis. Topical therapies include high-potency corticosteroids, and antiseptic or anesthetic solutions for mucosal involvement. Second-line therapies for patients who do not respond to antiviral medications include immunosuppressive agents, antibiotics, anthelmintics, and antimalarials

N'ọtụtụ oge, erythema multiforme dị nro na-apụ n'onwe ya n'ime izu 2 ruo 4. Ọrịa Stevens-Johnson, nke bụ ọnọdụ siri ike na-emetụta akpụkpọ anụ mucous, nwere ike ịdịru ruo izu isii. A naghị ekwu maka iji steroid n'obere ọnọdụ. Otú ọ dị, a ga-eji steroid mee ihe n'ọnọdụ erythema multiforme buru ibu, n'ihi na enweghị ihe akaebe doro anya sitere n'ọrụ nyocha na-enweghị usoro nke na-egosi na ụmụaka ga-erite uru site n'ogwu a.
In most cases, mild erythema multiforme is self-limited and resolves in 2 to 4 weeks. Stevens-Johnson syndrome is a serious disease that involves the mucous membranes and lasts up to 6 weeks. There is no indication for using steroids for the mild form. Use of steroids for erythema multiforme major is debatable because no randomized studies clearly indicate which children will benefit from this treatment.

Anyị na-egosi ikpe nke erythema multiforme (EM) nke kpatara TMP/SMX, nke gosipụtara ọnya ọnụ na egbugbere ọnụ na-enweghị ọnya anụ ahụ. Nke a na-egosi mkpa ọ dị ịmata ọdịiche ya na ọrịa ọnya afọ ndị ọzọ. Onye ọrịa ahụ nwetara ọgwụgwọ symptomatic na prednisolone, nke mere ka ọ dịkwuo mma mgbe a kwụsịrị TMP/SMX.
We report a case of oral erythema multiforme (EM) secondary to TMP/SMX that presented with oral and lip ulcerations typical of EM without any skin lesions and highlights the importance of distinguishing them from other ulcerative disorders involving oral cavity. The patient was treated symptomatically and given tablet prednisolone. The condition improved with stoppage of TMP/SMX therapy.

Erythema multiforme bụ mmeghachi omume metụtara akpụkpọ ahụ, na mgbe ụfọdụ mucosa, nke usoro ahụ ji alụso ọrịa ọgụ. Na-emekarị, ọ na-egosipụta dị ka ọnya ezubere iche, nke nwere ike ịpụta dịpụrụ adịpụ, na-emegharị ma ọ bụ na-adịgide. Ọnya ndị a na-emetụtakarị nsọtụ, ọkachasị elu ha. Isi ihe na-akpata ya gụnyere ọrịa dịka nje virus herpes simplex na Mycoplasma pneumoniae, yana ọgwụ ụfọdụ, ọgwụ mgbochi ọrịa, na ọrịa autoimmune. Ịmata ọdịiche erythema multiforme sitere na urticaria dabere na ogologo oge ọnya: erythema multiforme na-adịgide ma ọ dịkarịa ala ụbọchị asaa, ebe urticaria na-apụkarị n’ime otu ụbọchị. Agbanyeghị, ọ dị mkpa ịmata ọdịiche erythema multiforme na Stevens‑Johnson syndrome, nke na-egosipụtakarị erythematous ma ọ bụ purpuric macules nwere ọnya. Ijikwa erythema multiforme gụnyere enyemaka mgbaàmà, steroid ma ọ bụ antihistamines, yana ịchọpụta ihe kpatara ya. Maka ọrịa na-emegharị ugboro ugboro site n’nje virus herpes simplex, a na-atụ aro ọgwụgwọ prophylactic antiviral. Ọnọdụ siri ike nke mucosal nwere ike ịchọ ntinye ụlọ ọgwụ maka mmiri intravenous na nnọchi electrolyte.
Erythema multiforme is a reaction involving the skin and sometimes the mucosa, triggered by the immune system. Typically, it manifests as target-like lesions, which may appear isolated, recur, or persist. These lesions usually symmetrically affect the extremities, particularly their outer surfaces. The main causes include infections like herpes simplex virus and Mycoplasma pneumoniae, as well as certain medications, immunizations, and autoimmune diseases. Distinguishing erythema multiforme from urticaria relies on the duration of lesions; erythema multiforme lesions remain fixed for at least seven days, while urticarial lesions often vanish within a day. Although similar, it's crucial to differentiate erythema multiforme from the more severe Stevens-Johnson syndrome, which typically presents widespread erythematous or purpuric macules with blisters. Managing erythema multiforme involves symptomatic relief with topical steroids or antihistamines and addressing the underlying cause. For recurrent cases associated with herpes simplex virus, prophylactic antiviral therapy is recommended. Severe mucosal involvement may necessitate hospitalization for intravenous fluids and electrolyte replacement.